Adaptive Biotechnologies Announces a Collaboration with Janssen Biotech, Inc. to use the clonoSEQ® Assay to Measure Minimal Residual Disease in Ongoing and Future DARZALEX® Multiple Myeloma Trials
Adaptive Biotechnologies, the leader in combining Next Generation Sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has partnered with Janssen Biotech, Inc. to utilize Adaptive’s NGS-based clonoSEQ Assay for measuring minimal residual disease (MRD) in patients with Multiple Myeloma (MM) who have been treated with DARZALEX (daratumumab). DARZALEX is a CD38-directed cytolytic antibody approved for the treatment of patients with relapsed or refractory MM. Under the terms of the collaboration, Adaptive will receive an undisclosed upfront technology access payment in addition to development funding and potential future milestone payments. Adaptive will be responsible for seeking regulatory approvals for and commercialization of the clonoSEQ Assay in MM.
“Adaptive is thrilled to develop the technology to help measure the depth of response generated by DARZALEX in patients with MM,“ said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. “We look forward to advancing our strategic partnership with Janssen by incorporating the highly sensitive and quantitative clonoSEQ Assay into more trials with DARZALEX.”
Through this collaboration, the parties will work together to demonstrate the clinical utility of monitoring MRD negativity by the clonoSEQ Assay in MM patients who have been treated with DARZALEX, and to assess the medication’s ability to achieve MRD.
“Incorporating novel, proven molecular diagnostic tools into drug development and regulatory processes can enable clinicians to treat patients with the optimal interventions at the right time,” said Charles Sang, Adaptive’s Senior Vice President, Diagnostics. “Adaptive’s clonoSEQ Assay can help accomplish this goal due to the robust validation of the assay. We believe the shared commitment of both companies to monitor MRD negativity in patients with MM will drive the success of this collaboration.”
About Minimal/Measurable Residual Disease
Minimal/measurable residual disease (MRD) refers to cancer cells that remain in the body of a person with lymphoid cancer after treatment. These cells can be present at levels undetectable by traditional morphologic, microscopic examination of blood, bone marrow or a lymph node biopsy. Sensitive molecular technologies, such as next-generation sequencing utilized by the Adaptive Biotechnologies clonoSEQ Assay, are needed for reliable detection of MRD at levels below the limits of traditional assessment.
About the clonoSEQ ® Assay
The Adaptive Biotechnologies clonoSEQ Assay enables physicians to utilize next-generation sequencing-based minimal/measureable residual disease (MRD) detection to inform clinical decision making for patients with lymphoid malignancies. The clonoSEQ Assay detects and quantifies DNA sequences found in malignant cells which can be tracked throughout treatment. This robust assay provides consistent, accurate measurement of disease burden which potentially allows physicians to monitor response to treatment over time to optimize patient management. Adaptive will be seeking marketing authorization from the FDA for the clonoSEQ Assay.
About Adaptive Biotechnologies ®
Adaptive Biotechnologies is the pioneer and leader in combining in combining Next Generation Sequencing (NGS) and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information, please visit adaptivebiotech.com.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
GSMA Study: 5G to Account for a Third of Europe’s Mobile Market by 202517.10.2017 10:00 | Tiedote
More than 30 per cent of Europe’s mobile connections will be running on 5G networks by 2025, according to a new GSMA study. The 2017 Europe edition of the GSMA’s Mobile Economy series, published today at the GSMA Mobile 360 Series – Europe event in Brussels, forecasts that there will be 214 million 5G connections in Europe by 2025, establishing the region as one of the largest 5G markets in the world by that point. The first commercial 5G networks in Europe are due to be switched on by 2020 and are expected to provide 5G network coverage to almost three-quarters of Europe’s population by 2025. “Europe has an opportunity to reestablish itself as a global technology leader as we move toward the 5G era, but this can only happen if policymakers move quickly and boldly to make the necessary regulatory reforms to boost the region’s competitiveness on the global stage and bring innovative ser
REFLEX CES Partners with NOLAM EMBEDDED SYTEMS to Provide Integrated CANbus IP Core Solutions on FPGA COTS Boards17.10.2017 10:00 | Tiedote
NOLAM EMBEDDED SYSTEMS, manufacturer of semiconductor IP and board level products and systems for the Aerospace, Defense, telecom and industrial markets, today announced their partnership with REFLEX CES, a leading provider of complex, high-density FPGA-based boards. This partnership benefits customers by providing them a fully integrated solution based on REFLEX CES FPGA boards and NOLAM EMBEDDED SYSTEMS CANbus IP core and CANbus FMC module. «We are thrilled to collaborate with REFLEX CES to offer a fully integrated CANbus solution», stated Benjamin Nakache, Vice-President of Sales at Nolam Embedded Systems «By integrating our CANbus IP solution with our CANbus FMC to the REFLEX CES hardware, we bring a very easy-to use solution to CANbus users in the automotive industry.» One of the first outcomes of this collaborative venture is the release of an SDK, composed of REF
BNP Paribas Implements SmartStream’s TLM Fees and Expense Management Solution17.10.2017 10:00 | Tiedote
SmartStream, the Financial Transaction Lifecycle Management (TLM®) specialist, today announced that the Derivatives Execution & Clearing (DEC) business of BNP Paribas CIB has implemented its TLM Fees & Expense Management (FEMS) solution for two key objectives: To control and reconcile payable brokerage fees Invoice issuance to execute commissions for DEC clients FEMS will consolidate all fees which will be reconciled against invoices received. The solution will automate the invoice control process by managing the increase in volume growth and targeting essentially (1) the detection and resolution of disputes and (2) an acceleration of processing and payment turnaround time. Also, the solution will fully support the execution and commission billing process from DEC to its clients. Pierre Duret, Head of Clearing within BNP Pari
East and West Malaysia Gain Enhanced Mobile Broadband with SES Networks and CompuDyne17.10.2017 09:50 | Tiedote
CompuDyne, a leading telecommunications solutions provider in Malaysia, is partnering with SES Networks to bring high quality and cost-effective cellular backhaul service to both East and West Malaysia and its surrounding islands. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171016006356/en/ East and West Malaysia Gain Enhanced Mobile Broadband with SES Networks and CompuDyne (Photo: Business Wire) SES announced that CompuDyne has signed a multi-year, multi-transponder agreement to lease Ku-band capacity on SES-9, SES’s largest satellite dedicated to serve Asia-Pacific, for its customer Digi, the country’s leading mobile network operator. Making a shift from a C-band to Ku-band system, CompuDyne can now deliver more cost-effective and reliable satellite connectivity, enabling Digi
AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification17.10.2017 01:00 | Tiedote
AstraZeneca and its partner Chi-Med today presented preliminary safety and clinical activity of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib trials conducted in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with MET-amplification who had progressed following 1st-line treatment with an EGFR inhibitor.1,2 In both trials, the addition of savolitinib (600mg, once daily), an investigational selective inhibitor of c-MET (mesenchymal epithelial transition factor) receptor tyrosine kinase, to osimertinib (80mg, once daily) or gefitinib (250mg, once daily) demonstrated preliminary anti-tumour activity. The data were shared in two oral presentations at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan, 15-18 Oc
Orlando Melbourne Int’l (MLB) Lands Largest FAA Grant in Its History17.10.2017 00:34 | Tiedote
When Air Force One landed at Orlando Melbourne International Airport (MLB) in February, Airport Executive Director Greg Donovan took advantage of the opportunity and advised the president of the United States that his 747-200 just landed on a commercial runway officially rated ‘poor’ in aviation terms. That’s going to change, thanks to an $18,132,588 FAA grant announced by U.S. Secretary of Transportation Elaine Chao today. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171016006292/en/ Greg Donovan, A.A.E. (Photo: Business Wire) “We asked for, and received, tremendous support from the Florida congressional delegation,” said Jack L. Ryals, chairman of the Melbourne Airport Authority. “We are deeply grateful to Congressman Posey, Senator Nelson and Senator Rubio for their advocacy on this critic
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme